https://www.fiercebiotech.com/research/uk-team-sheds-light-how-anaptysbio-s-anti-il-33-eczema-drug-tamps-down-inflammation
Research
U.K. team sheds light on how AnaptysBio’s anti-IL-33 eczema drug tamps down inflammation
anti-IL-33
Promising therapy for common form of eczema identified in early-stage trial
https://www.imm.ox.ac.uk/about/news/promising-therapy-for-common-form-of-eczema-identified-in-early-stage-trial
https://medicalxpress.com/news/2019-10-therapy-common-eczema-early-stage-trial.html
Promising therapy for common form of eczema identified in early-stage trial
A therapy that targets the immune system showed promise for treating atopic dermatitis – the most common form of eczema – in a small proof-of-concept trial, led by scientists from the MRC HIU.
